ProCE Banner Activity

Frontline Brentuximab Vedotin + R-CHOP Yields High Response Rate in DLBCL

Slideset Download
Conference Coverage
In patients with previously untreated high-intermediate–risk or high-risk DLBCL, brentuximab vedotin + R-CHOP was associated with a response rate of 80%.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation